2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of Schrodinger Inc. (SDGR) based on the data provided.

**Schrodinger Inc. (SDGR) Overview:** Schrodinger is a company developing physics-based computational platform that enables discovery of novel molecules for drug discovery and materials applications.

**1) Return Rate Comparison:**

*   **SDGR Cumulative Return:** -54.41%
*   **VOO (S&P 500) Cumulative Return:** 64.25%
*   **Divergence:** -120.0 (Relative Divergence: 1.4)

**Analysis:** SDGR has significantly underperformed the S&P 500 over the period. The divergence of -120 indicates a substantial difference in returns. The relative divergence of 1.4 suggests the current divergence is near the lowest end of its historical range relative to its maximum fluctuations.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | -57.0% | 52.9% | -58.0% | 1.8 | 2.6 |
| 2022-2024  | 6.0% | 46.6% | -13.0% | 1.8 | 1.4 |
| 2023-2025  | -4.0% | 46.6% | -66.0% | 1.8 | 1.3 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate is negative for 2 of the 3 periods.
*   **MDD:** Maximum Drawdown is relatively high.
*   **Alpha:** Negative Alpha suggests underperformance relative to a risk-free investment, indicating SDGR is not generating excess returns.
*   **Beta:** A Beta consistently around 1.8 suggests SDGR is more volatile than the market (S&P 500).
*   **Cap(B):** Decrease in market capitalization.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 17.98
*   **Previous Close:** 17.88
*   **Change:** 0.56 (Slight increase)
*   **5-day SMA:** 17.96
*   **20-day SMA:** 18.03
*   **60-day SMA:** 18.78

**Analysis:** The current price is slightly above the 5-day SMA, slightly below the 20-day SMA, and significantly below the 60-day SMA. This suggests a potential short-term uptrend, but the longer-term trend is still downward. The small price change of 0.56 suggests no drastic fluctuation.

**3) Indicators Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 48.56 (Neutral)
*   **PPO:** 0.13 (Relatively neutral, indicating the stock isn't significantly overbought or oversold)
*   **Hybrid Signal:** 90% Buy, indicating a bullish recommendation based on the model, despite a high MRI.
*   **Recent Relative Divergence Change:** -0.4 (Short-term decline)
*   **Expected Return:** -4509.7% (Extremely negative expected return, suggesting significant risk)

**Analysis:** The MRI suggests a medium level of investment risk. The RSI is close to neutral, not signaling overbought or oversold conditions. The PPO is also neutral. The hybrid signal is confusing because is HIGHLY bullish but also states a "safe" approach. The recent divergence change points to a short-term downward trend. The expected return is extremely negative, indicating analysts expect the stock to significantly underperform the S&P 500.

**4) Recent News & Significant Events:**

*   **Positive Analyst Coverage:** Multiple articles highlight analyst upgrades (BofA) and price target increases.  This signals increased confidence from some analysts.
*   **"Buy the Bottom" Potential:** One article suggests SDGR might be a good "buy the bottom" stock, indicating it might be undervalued.
*   **Strategic Pivot to Software:** The BofA upgrade is based on a strategic pivot to software, suggesting the company is changing its focus, which investors may view favorably.
*   **AI-Powered Drug Discovery Comparison:** Comparison articles highlight the competitive landscape within the AI-powered drug discovery space.

**Analysis:** Recent news is mixed. There are positive signals from analyst upgrades and potential "buy the bottom" opportunities. However, the competitive landscape and shift in strategy introduce uncertainty.

**4-2) Analyst Opinions:**

*   **Mean Analyst Rating:** Not Available
*   **Average Price Target:** 27.22
*   **Price Target Range:** 18.00 - 33.00

**Analysis:** The price target range indicates a wide divergence of analyst opinions. The average price target is significantly above the current price, suggesting potential upside if analysts are correct. However, the lack of a mean analyst rating (1-5 scale) makes it difficult to gauge overall sentiment.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출    |
|------------|-------|---------|
| 2025-11-05 | -0.45 | 0.05 B$ |
| 2025-08-06 | -0.59 | 0.05 B$ |
| 2025-05-07 | -0.82 | 0.06 B$ |
| 2024-11-12 | -0.52 | 0.04 B$ |
| 2025-11-05 | -0.52 | 0.04 B$ |

**Analysis:** The company is consistently reporting negative EPS, indicating it is not currently profitable. Revenue is fluctuating, but not showing a clear growth trend.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.05B  | 51.61%        |
| 2025-06-30   | $0.05B  | 47.77%        |
| 2025-03-31   | $0.06B  | 52.26%        |
| 2024-12-31   | $0.09B  | 72.61%        |
| 2024-09-30   | $0.04B  | 50.24%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-09-30   | $0.32B  | -10.21%  |
| 2025-06-30   | $0.34B  | -12.59%  |
| 2025-03-31   | $0.37B  | -16.01%  |
| 2024-12-31   | $0.42B  | -9.54%   |
| 2024-09-30   | $0.45B  | -8.49%   |

**Analysis:**

*   **Revenue:** Revenue has fluctuated and is relatively low.
*   **Profit Margin:** Profit margins are high, indicating good cost control on sales, but ultimately does not result in positive income.
*   **Equity:** Equity is decreasing.
*   **ROE:** The Return on Equity is consistently negative, reflecting the company's lack of profitability.

**7) Comprehensive Analysis:**

Schrodinger Inc. (SDGR) presents a mixed investment picture.

**Negative Factors:**

*   **Significant Underperformance:** SDGR has significantly underperformed the S&P 500.
*   **Negative Earnings:** The company is consistently reporting negative earnings and negative ROE.
*   **Decreasing Equity:** Equity is decreasing, which is a concern.
*   **High Volatility:** The Beta of 1.8 indicates high volatility.
*   **Extremely Negative Expected Return:** The projected long-term return is severely negative.

**Positive Factors:**

*   **Analyst Upgrades:** Recent analyst upgrades and price target increases suggest some believe the company is undervalued.
*   **Potential "Buy the Bottom" Opportunity:** Some articles suggest the stock may be a good "buy the bottom" candidate.
*   **Strategic Pivot to Software:** The company's shift to software may be viewed positively by investors.
*   **High Profit Margins:** The high profit margins suggest good cost control in generating sales.

**Overall Conclusion:**

SDGR is a risky investment. While recent news suggests potential upside and some analysts are optimistic, the company's financial performance is concerning. The extremely negative expected return should be a major red flag for potential investors. Investors should proceed with caution and consider their risk tolerance carefully. The analyst upgrades, pivot to software, and potential "buy the bottom" scenario are speculative positives that need to be weighed against the hard financial data. Further research into the company's long-term strategy and ability to achieve profitability is warranted.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.